HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kang, J. H. Articles by Chung, J.-K. Search for Related Content PubMed PubMed Citation Articles by Kang, J. H. Articles by Chung, J.-K.

Molecular-Genetic Imaging Based on Reporter Gene Expression

¹ Department of Nuclear Medicine, Cancer Research Institute, Tumor Immunity Medical Research Center, College of Medicine, Seoul National University, Seoul, Korea; and ² Laboratory of Nuclear Medicine, Korea Institute of Radiological and Medical Science, Seoul, Korea

View larger version (9K): [in this window] [in a new window]   FIGURE 1.  Schematic explanation of disease progression and development of imaging modality. In many diseases, including cancer, genetic problem occurs first and then is followed by biochemical, functional, and morphologic changes. Conventional images can visualize anatomic morphologic change. SPECT, MRI, and PET can visualize functional physiologic change and biochemical change. Molecular-genetic imaging has been designed to visualize original genetic problem. MRS = MR spectroscopy.

View larger version (21K): [in this window] [in a new window]   FIGURE 2.  Schematic illustration of 3 types of reporter gene expression used in nuclear medicine modality. Representatives of enzyme type and transporter type are HSV1-tk (ovals) and NIS (squares), respectively. Receptor types are D2R, norepinephrine receptor, and SSTr2. Stars represent radioisotope-labeled substrates (enzyme) or ligands (receptor) or radionuclide itself (transporter type).

View larger version (94K): [in this window] [in a new window]   FIGURE 3.  PET/CT of adenovirus-mediated HSV1-tk expression in liver cancer patients. Treated tumor lesion is indicated by dotted lines on CT images, and 18F-FHBG accumulation at tumor site is indicated by arrows on PET images. White spots in liver on CT images (arrowheads) correspond to lipiodol retention after transarterial embolization of tumor and installation of transjugular intrahepatic portosystemic shunt (star). H = heart; L = liver; LB = large bowel; RL = right lung; Sp = spleen. (Reprinted with permission of (63).)

View larger version (22K): [in this window] [in a new window]   FIGURE 4.  Relationship between p53 gene expression and accumulation of radioiodine in SK-Hep1 cells expressing p53RE-hNIS (SK-Hep1p53NIS) after adriamycin treatment. (A) Western blot analysis and radioiodine uptake. After treatment of SK-Hep1p53NIS cells with adriamycin, 125I uptake of cells increased with increasing adriamycin dose. Levels of expression of total p53 and activated p53 (p53 Ser15) proteins increased in dose-dependent manner in SK-Hep1p53NIS cells. This increase in cells was completely inhibited by KClO4. (B) Scintigraphic images of endogenous p53 activation. Tumor xenografts were implanted in nude mice at 4 different sites: SK-Hep1 (a, 1 x 107, negative control); SK-Hep1p53NIS (b, 5 x 106; c, 1 x 107; d, 2 x 107). Scintigraphic images of 99mTc were obtained before and after adriamycin treatment in same mouse. Scintigraphy showed higher radioactivity in test tumors (SK-Hep1p53NIS) after adriamycin treatment than in control tumor (SK-Hep1). (C) Radioactivity ratio of SK-Hep1p53NIS to SK-Hep1 in mice before and after adriamycin treatment. Significantly higher uptake was observed in SK-Hep1p53NIS tumors than in SK-Hep1 tumor after adriamycin treatment or in nontreated SK-Hep1p53NIS tumors.

View larger version (72K): [in this window] [in a new window]   FIGURE 5.  99mTc scintigraphic images (A) and bioluminescent images (B) of nude mice bearing SK-Hep1 and SK-Hep1/RARE/NIS-Luc tumors before and after all-trans-retinoic acid (ATRA) treatment. Tumor xenografts derived from SK-Hep1 cells (a, 1 x 107, wild type) and SK-Hep1/RARE/NIS-Luc cells (b, 1 x 106; c, 1 x 107; d, 1 x 108) were grown in nude mice. (A) Serial planar -camera images of same mouse show increased radioactivity after ATRA treatment in SK-Hep1/RARE/NIS-Luc tumors but not in SK-Hep1 tumor. (B) Serial optical images of same mouse show increased optical signal after ATRA treatment in SK-Hep1/RARE/NIS-Luc tumors but not in SK-Hep1 tumor. Bl = bladder; St = stomach; Thy = thyroid.

View larger version (32K): [in this window] [in a new window]   FIGURE 6.  Correlation between imaging signals from tumors and tumor weight. SK-Hep1 and SK-Hep1/NIS-Luc cells expressing simultaneously NIS and luciferase genes were implanted as xenografts into left shoulder (SK-Hep1; 5 x 106 cells), right shoulder (SK-Hep1/NIS-Luc; 5 x 106 cells), left thigh (SK-Hep1/NIS-Luc; 1 x 107 cells), and right thigh (SK-Hep1/NIS-Luc; 5 x 106 cells). (A) 99mTc scintigraphic images show increased radioactivity in SK-Hep1/NIS-Luc tumors but not in SK-Hep1 tumor. After acquisition of scintigraphic images, mice were sacrificed, and biodistribution of radioactivity was examined. Correlation between tumor weight and radioactivity of each tumor is shown (R2 = 0.8661). (B) Bioluminescent images show viable tumor burden of SK-Hep1/NIS-Luc tumors but not of SK-Hep1 tumor. Correlation between bioluminescence signal and tumor weight was moderate (R2 = 0.7114).

View larger version (61K): [in this window] [in a new window]   FIGURE 7.  Molecular imaging of cardiac cell transplantation in rat using optical bioluminescence and PET. (A) After transplantation into rat of embryonic cardiomyoblasts expressing luciferase gene, luciferase images were obtained for 16 d at cardiac site. Control rat showed background signal only. (B) After transplantation with cardiomyoblasts expressing HSV1-sr39tk reporter gene, location(s), magnitude, and duration of gene expression could be monitored by PET with 18F-FHBG (gray scale). (C) Representative rat with transplant had significant activity at lateral wall, as shown by 18F-FHBG image (color scale) overlaid on 13N-NH3 perfusion image (gray scale). Control rat had homogeneous 13N-NH3 perfusion but background 18F-FHBG activity. (D) Autoradiography of same rat confirmed accumulation of 18F-FHBG at lateral wall. %ID/g = percentage injected dose per gram. (Reprinted with permission of (92).)

View larger version (35K): [in this window] [in a new window]   FIGURE 8.  Development of NIS-transgenic mice for cardiomyocyte-specific reporter gene expression. (A) To verify cell-type-specific expression of pMHC-NIS vector, pMHC-NIS was transfected into 2 rat myoblast cell lines, L6 and H9c2, and human hepatoma cell line, SK-Hep1. Transfected L6 and H9c2 cells showed 20-fold- and 10-fold-higher 125I uptake than their parental cells, but hepatoma did not (inset). Therefore, the MHC promoter was confirmed to be active only in cardiomyocytes. (B) Small-animal PET image obtained for transgenic mouse with 124I (left, transverse; center, coronal; right, sagittal). Transgenic mouse showed higher uptake of 124I in heart (H) than in thyroid (T) or stomach (S). pcDNA-NIS = control.